// App-Quantinova.ai

1681 : Pegcetacoplan Is Superior to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Regardless of Prior Transfusion Requirement

Researchers

Presenter

  • Regis Peffault De Latour

Principal Investigators

  • Carlos M. de Castro

  • Jeffrey Szer

  • Kensuke Usuki

  • Peter Hillmen

  • Morag Griffin

  • Mohamed Hamdani

  • Temitayo Ajayi

  • Hisakazu Nishimori

  • Ilene C. Weitz

Medical Centers

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France

  • Duke University College of Medicine, Durham, NC

  • Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

  • Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • AMAG Pharmaceuticals, Inc., Waltham, MA

  • Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan

  • Jane Anne Nohl Division of Hematology, Keck School Of Medicine of USC, Los Angeles, CA

Locations

  • France

  • United States

  • Australia

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Anemia

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03500549

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved